To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107

February 7, 2025 updated by: JW Pharmaceutical

A Randomized, Open-label, Single Dose, 2x4 Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of JW0106 and C2101 and Administration of JW0107 in Healthy Volunteers Under Fasting Conditions

The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0106 and C2101 and administration of JW0107 in healthy volunteers under fasting conditions.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Pharmacokinetic characteristics: Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.

Safety: All adverse events are summarized in terms of the number of subjects, expression rate, and number of expressions of adverse reactions by treatment group.

Study Type

Interventional

Enrollment (Actual)

47

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Korea, Republic of
    • Korea
      • Jeonju, Korea, Korea, Republic of
        • Clinical Trial Center, Jeonbuk National University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Healthy volunteers

Exclusion Criteria:

Subjects does not meet the inclusion Criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Sequence 1

(Period 1/3: Treatment A) (Period 2/4: Treatment B)

Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet
Drug: Treatment A: JW0106 1 tablet + C2101 1 tablet
  • Co-administration of 1 tablet of JW0106 and 1 tablet of C2101
  • Administration orally with 150 mL of water under fasting conditions
Drug: Treatment B: JW0107 1 tablet
  • Administration alone of 1 tablet of JW0107
  • Administration orally with 150 mL of water under fasting conditions
Other Names:
  • Administration alone of 1 tablet of JW0107
Other: Sequence 2

(Period 1/3: Treatment B) (Period 2/4: Treatment A)

Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet
Drug: Treatment A: JW0106 1 tablet + C2101 1 tablet
  • Co-administration of 1 tablet of JW0106 and 1 tablet of C2101
  • Administration orally with 150 mL of water under fasting conditions
Drug: Treatment B: JW0107 1 tablet
  • Administration alone of 1 tablet of JW0107
  • Administration orally with 150 mL of water under fasting conditions
Other Names:
  • Administration alone of 1 tablet of JW0107

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
AUCt
Time Frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Cmax
Time Frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Describes the blood concentration statistically by pharmacokinetic blood
Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

JW Pharmaceutical

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 2, 2024

Primary Completion (Actual)

November 2, 2024

Study Completion (Actual)

November 12, 2024

Study Registration Dates

First Submitted

January 1, 2025

First Submitted That Met QC Criteria

February 7, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 7, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • JW24107

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Treatment A: JW0106 1 tablet + C2101 1 tablet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe